Lantern Pharma is trading at $2.90 (10.3% up) following momentum from the European Medicines Agency (EMA) clearing a Phase 1b/2 trial for its lead candidate, LP-184.
- The trial will evaluate LP-184 in patients with advanced, recurrent bladder cancer, representing a significant regulatory milestone for the company's clinical development.
- The stock is rebounding after a volatile week for small-cap biotech firms, with the regulatory news driving increased speculative interest in the pre-market session.